The Ministry of Science, Technology and Innovation (MOSTI), through the Atomic Energy Department, has responded to claims of ...
Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), as a new first-line maintenance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results